Celltrion Obtains Domestic Approval for Product Modification of COVID-19 Treatment 'Rekkirona J'

[Asia Economy Reporter Oh Hyung-gil] Celltrion announced on the 17th that it has obtained domestic product modification approval for the COVID-19 virus (SARS-CoV-2) treatment 'Rekkironaju (CT-P59)' from the Ministry of Food and Drug Safety.

The company stated, "In the situation where confirmed cases are increasing due to the prolonged COVID-19 pandemic, demand for treatments is expected to remain steady. It can contribute to normalizing the COVID-19 situation by reducing the rate at which existing patients' symptoms worsen to severe conditions or death." They added, "We plan to apply for emergency use authorization and approval in each country through continuous discussions with global regulatory agencies."